DSM Pharmaceuticals Appoints New CEO - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DSM Pharmaceuticals Appoints New CEO



DSM Pharmaceutical Products, the contract manufacturing organization of Royal DSM, appointed Lukas Utiger, PhD as its new CEO and President, effective Oct. 1, 2013.

Headquartered in Parsippany, NJ, the DSM Pharmaceutical Products business group includes DSM Biologics/BioSolutions, DSM Pharma Chemicals, DSM Exclusive Synthesis & Intermediates, and DSM Pharmaceuticals with operations in the US, Europe, and Australia.

Utiger has 25 years of industry experience, managing both small- and large-molecule manufacturing, as well as research and development.

Prior to joining DSM, Utiger was responsible for Lonza’s Bioscience division, where for more than 10 years he also served on the executive committee for various divisions including the pharma contract manufacturing organization and nutrition.

Source: DSM Pharmaceutical

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here